Brain Metastasis
45
8
8
13
Key Insights
Highlights
Success Rate
59% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
20.0%
9 terminated out of 45 trials
59.1%
-27.4% vs benchmark
9%
4 trials in Phase 3/4
31%
4 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (45)
Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases
NK Cell Therapy for Malignant Solid Brain Tumors
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
18F-FLUC PET/MR in Patients With Brain Mets
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
Feasibility of a Cognitive Stepped Care Program for Adults With Brain Metastases
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Evaluation of Neoadjuvant Stereotactic Radiosurgery (SRS) and Multi-fraction SRS Alone for the Treatment of Large Brain Metastases
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases
Brain Metastasis Development Mechanism in BCBM Patients
Study of Whole-brain Irradiation With Chloroquine for Brain Metastases
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis